Illumina, Nanosys, Paradigm

May 02, 2003

Premium

Illumina Revenues Up

Illumina reported increased revenues for the first quarter last week, amid nearly flat net losses.

The San Diego genotyping and oligonucleotide company’s revenues for the quarter totaled $4.3 million, up from $1.3 million for the year-ago quarter. Net losses totaled $9.0 million, up from $8.7 million for the first quarter of 2002. Research and development expenses were $5.7 million, from $7.1 million in Q1 2002.

Nanosys GET New Funders in $30M Series B

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

Prize for Five

Five researchers are to share this year's Albany Medical Center Prize for their work on the CRISPR/Cas9 gene-editing tool, the AP reports.

Sure, Blame the Test

Stat News reports on how white supremacists cope with surprising genetic ancestry testing results.

This Week in Genome Research

In Genome Research this week: sex-biased gene expression evolution in malaria mosquitos, method to find ancient selective sweeps, and more.

Low Down Syndrome Rates in Iceland

Iceland has nearly eliminated Down syndrome from its population, CBS News reports.

Featured White Papers

Compatibility of CYTAG CGH Labeling Kit with Illumina 24sure Microarrays

Optimized NGS Library Preparation with Acoustic Liquid Handling

Main menu